May 6, 2009

Bullish on Myriad Genetics

Zacks is bullish on Myriad Genetics, giving the stock a $50 price target. From the article:

"Molecular diagnostics has enjoyed a boom in the past few years and will continue its momentum in the coming years, in our view, when targeted therapy has become more accepted in the healthcare community. We believe Myriad Genetics, along with other molecular diagnostics firms, will ride the wave of high growth in this industry in the coming years."

No comments: